Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Abdelshafy Tabl, Ahmed https://orcid.org/0000-0003-1435-3918
Rihani, Heba T.
Tabl, Marwa Abdelshafy
Shebl, Ahmed A.
Abousaif, Walid Samir
Elfalah, Mutasem
Shaf”ei, Moayad
AlSaadi, Tabarak
,
Khanani, Arshad M.
Eichenbaum, David
Regillo, Carl
Boyer, David
Kuppermann, Baruch D.
Loewenstein, Anat
Bandello, Francesco
Querques, Giuseppe
Ueda-Consolvo, Tomoko
Ishida, Masaaki
Nakamura, Tomoko
Hayashi, Atsushi
Tsuboi, Kotaro
Kumar, Nilesh
Parachuri, Nikulaa
Sheth, Jay
Mishra, Chitaranjan
Chakraborty, Debdulal
Banker, Alay
Rezaei, Kourous A.
Kaiser, Peter K.
Holz, Frank G.
Sivaprasad, Sobha
Özdek, Şengül
Laurent, Kodjikian
Bilgic, Alper
Lanzetta, Paolo
Sarao, Valentina
Baumal, Caroline
Holekemp, Nancy
Sakamoto, Taiji
Tufail, Adnan
Yannuzzi, Nicolas
Corradetti, Giulia
Rachitskaya, Aleksandra
Peto, Tunde
Wintergerst, Maximilian WM
Parolini, Barbara
Nguyen, Quan Dong
Diana, V. D.
Keane, Pearse A.
Hassan, Tarek
Grewal, Dilraj S.
March, Francesc
Spitzer, Martin S.
Falavarjani, Khalil G.
Zinkernagel, Martin S.
Lee, Christopher Seungkyu
Kim, Judy E.
Woo, Se Joon
Nicholson, Luke
Vazquez-Alfageme, Clara
Wakabayashi, Taku
- License Information
-
More Information
Article History
Received: 31 March 2026
Revised: 15 April 2026
Accepted: 7 May 2026
First Online: 16 May 2026
Competing interests
: AS: Consultant for Oculis, Novartis, Allergan, Bayer, Lupin, Intas, Ajanta and Sun Pharma Speaker fee MS Pharma, Abdi İbrahim İlaç San. ve Tic, Samil Pharma, Roche. AAT, HTR, MAT, AAS, WSA, ME, MS, TAlS- None.
: During the preparation of this manuscript, the author used ChatGPT (OpenAI) to improve language clarity and editorial expression. After using this tool, the author carefully reviewed and edited the content as needed and takes full responsibility for the integrity and accuracy of the final manuscript.
